Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2 a: Ribavirin therapy

Journal of Viral Hepatitis

Volumn 15, Issue 8, 2008, Pages 591-599

  Derbala, M F ^a,b   Dweik, N Z El ^a   Kaabi, S R Al ^a   Al Marri, A D ^c   Pasic, F ^a   Bener, A B ^c   Shebl, F M ^c   Amer, A M ^d   Butt, M T ^a   Yakoob, R ^a   John, A ^a   Mohanadi, M Al ^a   Khinji, M A Al ^b  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Powertrain R and D Center   (South Korea)

Author keywords

Genotype 4; HCV; Viral kinetic

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 64549090121     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00988.x     Document Type: Article

References (28)

1. National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C. Hepatology 2002; 36: S3-S20.
2. Hadziyannis SJ, Sette HJ, Morgan TR et al. Peginterferon-alpha 2a and Ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and Ribavirin dose. Ann Intern Med 2004; 140(5): 346-355.
3. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004; 53: 15-18.
4. Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 hepatitis C virus. J Infect Dis 2000; 182: 28-35.
5. Legrand-Abravanel F, Nicot F, Boulestin A et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005; 77(1): 66-69.
6. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37(6): 1343-1350.
7. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 5(Suppl. 1): S145-S151.
8. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37(6): 1351-1358.
9. Herrmann E, Zeuzem S. Hepatitis C viral kinetic models. Cell Death Differ 2003; 10(Suppl. 1): S7-S8.
10. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
11. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus riba-virin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 year. Am J Gastroenterol 2007; 31 [Epub ahead of print].
12. Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005; 12(4): 380-385.
13. Derbala M, Al Kaabi S, El Dweik N et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12(35): 5692-5698.
14. Koda M, Murawaki Y, Kawasaki H, Ikawa S. Portal blood velocity and portal blood flow in patients with chronic viral hepatitis: relation to histological liver fibrosis. Hepatogast-roenterology 1996; 43: 199-202.
15. Lee CM, Kee KM, Hung CH et al. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection. Antivir Ther 2006; 11(1): 17-23.
16. Takatori M, Sugata F, Okuse C, Iwabuchi S, Iino S. Mutations in the non-structural protein 5A gene in patients with chronic hepatitis C virus 1b infection during repeated interferon treatment. Hepatol Res 2000; 18(3): 276-283.
17. Genovese D, Dettori S, Argentini C et al. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol 2005; 43(4): 1902-1909.
18. Ukai K, Ishigami M, Yoshioka K et al. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphoryla-tion homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load. World J Gastroenterol 2006; 12(23): 3722-3728.
19. Karino Y, Toyota J, Sugawara M et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003; 18(4): 404-410.
20. Layden JE, Layden TJ, Reddy KR Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002; 9(5): 340-345.
21. Tsubota A, Arase Y, Someya T et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75(1): 27-34.
22. Carlsson T, Reichard O, Norkrans G, et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with egylated interferon-alpha 2a and ribavirin according to vi-rological response. J Viral Hepat 2005; 12(5): 473-480.
23. Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginter-feron alpha 2a. Gastroenterology 2001; 120(6): 1438-1447.
24. Moreno A, Ba′rcena R, Garci′a-Garzo′n S et al. Viral kinetics and early prediction of nonresponse to peg-IFN-a-2b plus ribavirin in HCV genotypes 1/4 according to HIV serosta-tus. J Viral Hepat 2006; 13: 466-473.
25. Ouzan D, Khiri H, Penaranda G, Joly H, Halfon P. Kinetics of hepatitis C virus RNA load during pegylated interferon al-pha-2a and ribavirin treatment in naive genotype 1 patients. Comp Hepatol 2005; 4: 9.
26. Kamal SM, El Kamary SS, Shardell MD et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; [Epub ahead of print].
27. Yu JW, Jian-Wu Yu, Wang G, Sun L, Li X, Shu-Chen L. Predictive value of rapid virological response and early vi-rological response on sustained virological response in HCV patients treated with pegylated interferon a-2a and ribavi-rin. J Gastroenterol Hepatol 2007; 22(6): 832-836.
28. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 1351-1358.